| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | HH20; FGF-13 |
| WB Predicted band size | 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human FGF17 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FGF17抗体的示例性参考文献(注意：以下内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*FGF17 Antibody Reveals Its Role in Cortical Neurogenesis*
**作者**：Smith A, et al.
**摘要**：本研究利用特异性FGF17抗体探究其在哺乳动物大脑皮层发育中的作用。实验表明，FGF17通过调控神经干细胞的分化影响皮质层形成，抗体阻断实验进一步验证了其对Wnt/β-catenin通路的调控机制。
---
2. **文献名称**：*Targeting FGF17 with Neutralizing Antibodies Inhibits Colorectal Cancer Progression*
**作者**：Chen L, et al.
**摘要**：通过开发高亲和力FGF17中和抗体，研究发现抑制FGF17信号可显著减少结直肠癌模型中的肿瘤血管生成和转移，提示FGF17抗体在癌症治疗中的潜在应用。
---
3. **文献名称**：*FGF17-FGFR2 Interaction in Bone Development: Insights from Antibody-Based Inhibition Studies*
**作者**：Yamamoto K, et al.
**摘要**：利用FGF17特异性抗体阻断FGF17与FGFR2的结合，揭示了FGF17在骨生长板中的关键作用，为骨骼发育异常相关疾病的治疗提供新靶点。
---
4. **文献名称**：*FGF17 Antibody Application in Cardiac Regeneration Models*
**作者**：Gupta R, et al.
**摘要**：在小鼠心肌损伤模型中，FGF17抗体的局部注射被证实可抑制过度纤维化并促进心肌细胞再生，为心脏修复策略提供了实验依据。
---
**提示**：实际研究中需通过PubMed、Web of Science等平台检索真实文献，结合关键词如“FGF17 antibody”, “FGF17 function”等获取最新进展。
Fibroblast Growth Factor 17 (FGF17) is a member of the FGF family, which comprises 23 secreted signaling proteins regulating cell proliferation, differentiation, survival, and metabolism. FGF17 belongs to the FGF8 subfamily (FGF8. FGF17. FGF18) and functions primarily through binding to FGF receptors (FGFRs) in complex with heparan sulfate proteoglycans. It plays critical roles during embryonic development, particularly in midbrain and limb patterning, as well as in adult tissue homeostasis. Dysregulation of FGF17 has been implicated in developmental disorders, metabolic diseases, and cancers, including colorectal and prostate malignancies.
FGF17 antibodies are immunological tools designed to detect, quantify, or modulate FGF17 activity. Polyclonal and monoclonal variants are widely used in research to study FGF17's spatial-temporal expression patterns via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Neutralizing antibodies specifically block FGF17-FGFR interactions, enabling functional studies to dissect its signaling pathways or assess therapeutic potential. Recent interest in FGF17-targeting antibodies stems from their potential application in treating FGF17-driven pathologies. For example, preclinical studies explore their utility in suppressing tumor growth or mitigating aberrant FGF signaling in skeletal disorders. However, challenges remain in ensuring antibody specificity, minimizing off-target effects on related FGF family members, and optimizing delivery strategies for clinical translation.
×
